Power Law company profile

Micromet

Biotech & Life Sciences · Carlsbad, United States · Founded 1993 · IPO 2006 Unicorn

Biopharmaceutical company focused on developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026

Investors

9 investors on Micromet's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Seed 3 investors entered at this stage

Atlas Venture

Abingworth

3i Group

Series A 1 investor entered at this stage

SV Health Investors

Series B+ 5 investors entered at this stage

Vector Fund Management

Ludwig Maximilian University of Munich

JP Morgan

Forward Ventures

Amerindo Investment Advisors

Global footprint

Where Micromet has talent and traffic

Workforce by country

🇺🇸 United States · Carlsbad HQ

Book a demo for the full country breakdown

Patent intelligence

$85M patent portfolio · 16 active families

Estimated portfolio value

$85M

9.2× smaller than top peer BioNTech ($780M)

16 active patent families

Where Micromet innovates Molecular biologyPharmaceutical drugSingle chainAmino acidDisease

Where Micromet concentrates vs peers

Each axis is a top-10 topic across Micromet and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Micromet

An AI-synthesized read of the highest-engagement posts about Micromet on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Micromet on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles